Skip to main content
SpringerLink
Log in

First-line biologic not cost effective versus triple therapy for RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

  2. biological DMARDs

References

  1. Bansback N, et al. Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. Annals of Internal Medicine 167: 8-16, No. 1, 4 Jul 2017. Available from: URL: http://doi.org/10.7326/M16-0713

    Article  PubMed  Google Scholar 

  2. Losina E, et al. Improvement at Any Cost? The Art and Science of Choosing Treatment Strategies for Rheumatoid Arthritis. Annals of Internal Medicine 167: 55-56, No. 1, 4 Jul 2017. Available from: URL: http://doi.org/10.7326/M17-1176

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

First-line biologic not cost effective versus triple therapy for RA. PharmacoEcon Outcomes News 783, 18 (2017). https://doi.org/10.1007/s40274-017-4189-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4189-z

Search

Navigation